1. Market Research
  2. > Pharmaceutical Market Trends
Peptide Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Peptide Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • February 2021
  • 133 pages
  • ID: 6028503
  • Format: PDF
  • Mordor Intelligence LLP
Up to $750 off Until Apr 20th 2021

Summary

Table of Contents

Search Inside

The Peptide Therapeutics Market is valued at approximately USD 28,510.60 million in 2020 and is expected to witness a revenue of USD 51,360.30 million in 2026, with a CAGR of 9.66% over the forecast period (2021-2026).

Novel peptides are being developed and repurposed as therapeutics for the treatment of COVID-19. Globally, researchers continue to search for compounds that either block the mechanisms important for SARS-CoV-2 infection and replication or treat conditions caused by the infection. On 21 February 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. as of May 2020, there were 21 peptide drugs in development for the treatment of Covid-19, including 15 synthetic peptides in development for the treatment of Acute Respiratory Distress Syndrome (ARDS), and other respiratory illnesses caused by SARS-Cov-2 infection. Hence, COVID–19 might have a positive impact on the peptide therapeutics market as peptide drugs are being considered as a treatment option for dealing with COVID-19. However, the current applications of peptide therapeutics in oncology, metabolic disorders, etc. have been disrupted due to a shortage of drugs and supply chain issues, along with the slow progress of clinical trials related to non-COVID-19 therapeutics.

The increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics are the major factors driving the market growth. According to the World Health Organization (WHO), Chronic diseases such as cancers, cardiovascular diseases, diabetes are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes and in 2020, the contribution of chronic diseases is estimated to have caused 73% of all deaths and 60% of the global burden of disease. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn is expected to drive the growth of the peptide therapeutics market. However, instability issues of peptide therapeutics and the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restraint market growth.

Key Market Trends
Cancer Application is Expected to Register the Highest CAGR Over the Forecast Period.

Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.

According to the International Agency Research on Cancer- GLOBOCAN 2020 report, the total number of 19,292,789 new cancer cases were diagnosed worldwide in 2020, with 9,958,133 deaths due to cancers. Also, the five-year prevalent cases of cancers were estimated to be 50,550,287 globally. The number of new cancer cases is expected to reach 28,887,940 by 2040 worldwide. Thus, the high prevalence of cancers globally plays a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for growing focus towards alternative therapeutics such as peptide-based drugs.

However, according to the research article published in Nature Cancer, 2020, the COVID-19 pandemic is expected to have disrupted the spectrum of cancer care, including delayed diagnoses, treatment, and halting clinical trials aimed at developing efficient therapeutics for cancer treatment, within which peptide therapeutics for cancer treatment is of no exception. Hence, the studied segment is predicted to be significantly impaired during the pandemic.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutics products, increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry.

Increasing research and development expenditure by government and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical & pharmaceutical industry in this region is a major factor responsible for growth. In the North America region, the United States holds the largest market share due to factors such as an increasing number of research programs in the medical industry, along with a growing number of diseases in the country, which is anticipated to stimulate the demand in this region. According to the estimates of the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases were diagnosed, and 606,520 cancer deaths were reported in the United States. Owing to the increasing burden of cancer the demand for peptide therapeutics is expected to grow.? Furthermore, according to the study “Therapeutic peptides: Historical perspectives, current development trends, and future directions” published in 2018, it has been found that there are over 60-70 peptides that are being approved in the United States, and around over 150 are in active clinical development, and an additional 260 have been tested in human clinical trials. This data indicates that peptides are becoming increasingly known to the healthcare industry in the United States and peptides continue to enter clinical development at a steady pace. Hence, given the aforementioned factors, the Peptide therapeutics market is expected to witness significant growth in North America over the forecast period.

However, according to the research article published in Applied Clinical Trials, in Oct 2020, the COVID-19 pandemic caused major disruptions to clinical trial execution in the United States, impacting key stakeholders across the healthcare industry. The Sponsors, CROs, and other organizations that support drug development shifted to remote working environments and an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. Hence, COVID-19 is expected to have a significant impact on the non-Covid-19 peptide therapeutics market in the region during the pandemic.

Competitive Landscape
The peptide therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Bristol-Myers Squibb Company, EVER NEURO PHARMA GMBH, Takeda Pharmaceutical Company Limited, and many others. The major players are involved in strategic alliances such as acquisitions and collaborations, along with research activities for the global expansion of the product portfolio. For instance, in June 2019, Eli Lilly and Company received the FDA approval for Emgality, a subcutaneously injected calcitonin gene-related peptide (CGRP) antibody for migraine prevention and for the treatment of episodic cluster headache.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

$4250

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Alginate Market By Type, By Product, By Application, By Region, Industry Analysis and Forecast, 2020 - 2026

  • $ 3600
  • January 2021
  • 188 pages

The Global Alginate Market size is expected to reach $961.4 Million by 2026, rising at a market growth of 8% CAGR during the forecast period. Alginates are a set of naturally occurring anionic polysaccharides, ...

  • World
  • APAC
  • Beverage
  • Propylene Glycol
  • Industry analysis
  • Health Expenditure
  • Food Production

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on